MCRB - セレス・セラピュ―ティックス （Seres Therapeutics Inc.）

A share of Seres Therapeutics Inc. (NASDAQ:MCRB) closed at $7.05 per share on Monday, down from $7.15 day before. While Seres Therapeutics Inc. has underperformed by -1.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -24.60%, with highs and lows ranging from $11.69 […]

Gainers: Kala Pharmaceuticals (KALA) +19%. Alphabet (GOOGL) +7%

Seres Therapeutics Inc. (NASDAQ:MCRB) marked $7.06 per share on Wednesday, up from a previous closing price of $6.64. While Seres Therapeutics Inc. has overperformed by 6.33%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -26.38%, with highs and lows ranging from $11.69 to […]

Seres Therapeutics Inc. (NASDAQ:MCRB) closed Friday at $7.17 per share, down from $7.50 a day earlier. While Seres Therapeutics Inc. has underperformed by -4.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -5.41%, with highs and lows ranging from $11.69 to $2.50, whereas […]

Seres Therapeutics Inc. (NASDAQ:MCRB)’s traded shares stood at 1.39 million during the last session, with the company’s beta value hitting 2.79. At the close of trading, the stock’s price was $7.50, to imply an increase of 5.34% or $0.38 in intraday trading. The MCRB share’s 52-week high remains $11.69, putting it -55.87% down since that … Seres Therapeutics Inc. (NASDAQ: MCRB)’s -16.57-Percent Loss Of This Past Week Taught Us Something New Read More »

Seres Therapeutics (MCRB) shares dropped ~8% pre-market after the microbiome therapeutics company launched a $100M offerinf of common stock.Then offering consists of 31,746,030 shares…

Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%

Redbox Entertainment (RDBXW) +70%. Sidus Space (SIDU) +45%.Redbox Entertainment (RDBX) +18%. Seres Therapeutics (MCRB) +13%. Checkpoint Therapeutics (CKPT) +12%

Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection. Read more on MCRB stock here.

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC ) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company''s pūrgo technology, classifying it as a class II medical device. Applied UV, Inc. (NASDAQ: AUVI ) gained 96.4% to close at $2.18. Kiromic BioPharma, Inc. (NASDAQ: KRBP ) shares jumped 74.3% to close at $0.5020 on Tuesday after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic''s Gamma Delta T cell allogeneic therapies. JanOne Inc. (NASDAQ: JAN ) shares gained 62.8% to settle at $4.07 after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) rose 61.8% to close at $1.15. Accelerate Diagnostics, last month, posted a Q1 loss of $0.25 per share. Oncorus, Inc. (NASDAQ: ONCR ) rose 48.7% to close at $1.65. Energy Focus, Inc. (NASDAQ: EFOI ) gained 46.2% to settle at $2.28.

Seres Therapeutics, Inc. (NASDAQ:NASDAQ:MCRB) Q1 2022 Earnings Conference Call May 04, 2022 08:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President…

Seres Therapeutics press release (MCRB): Q1 GAAP EPS of -$0.61 misses by $0.09.Revenue of $1.49M (-74.0% Y/Y).

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “Seres continued to make important progress toward bringing SER-109 to patients suffering with recurrent C. difficile infection (rCDI). Given the robust profile of SER-109 observed in our Phase 3 study, we expect the product to have a significant impact on rCDI, a serious disease with approximate

Seres Therapeutics (MCRB) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open.The consensus EPS Estimate is -$0.50 (-28.2% Y/Y) and the consensus…

In last trading session, Seres Therapeutics Inc. (NASDAQ:MCRB) saw 0.62 million shares changing hands with its beta currently measuring 3.40. Company’s recent per share price level of $4.73 trading at -$0.14 or -2.87% at ring of the bell on the day assigns it a market valuation of $465.95M. That closing price of MCRB’s stock is … Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months Read More »